The BRAVE-AA-PEDS trial found that once-daily baricitinib significantly improved hair regrowth on the scalp, eyebrows, and ...

A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and ...

For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 ...

In an alopecia areata trial, a novel bifunctional therapy that blocks signaling of the interleukin-7 and TSLP pathways ...

ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...

Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...

In an interview with Brittany Craiglow, MD, FAAD, dermatologist at Dermatology Physicians of Connecticut in Fairfield, she advocates for combination therapies using baricitinib to treat pediatric ...

Eli Lilly just scored a major win with its Phase 3 BRAVE-AA-PEDS study. The trial confirmed baricitinib's effectiveness in ...

Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...

A woman has shared how she hides her bald patches so well that you can't tell she has alopecia. Hair is a big part of many ...

The rising prevalence of prediabetes among young adults signals early metabolic dysfunction, significantly increasing the ...

Researchers have developed a compound that could potentially treat the autoimmune disorder alopecia, which causes hair loss ...